As of 2025-12-25, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -69.97 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 13.21 CAD, the upside of Briacell Therapeutics Corp is -629.69%.
Based on its market price of 13.21 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 629.69%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -69.97 - -69.97 | -69.97 | -629.69% |
| DDM - Stable | (100.98) - (336.93) | (218.96) | -1757.5% |
| DDM - Multi | (84.66) - (231.06) | (125.28) | -1048.4% |
| Market Cap (mil) | 24.83 |
| Beta | 3.77 |
| Outstanding shares (mil) | 1.88 |
| Enterprise Value (mil) | 24.83 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.72% |
| Cost of Debt | 5.00% |
| WACC | 7.20% |